Myeloma drugs removed from Cancer Drugs Fund

NHS England has announced that Imnovid┬« (pomalidomide) for relapsed and refractory myeloma patients and Revlimid┬« (lenalidomide) for treatment at first relapse will no longer be available via the Cancer Drugs Fund (CDF) following a recent reassessment of the cancer drugs being funded this way. This applies only to patients in England, which will take effect…

Details